CD8+ T cell activation in cancer comprises an initial activation phase in lymph nodes followed by effector differentiation within the tumor
Prokhnevska N, Cardenas M, Valanparambil R, Sobierajska E, Barwick B, Jansen C, Reyes Moon A, Gregorova P, delBalzo L, Greenwald R, Bilen M, Alemozaffar M, Joshi S, Cimmino C, Larsen C, Master V, Sanda M, Kissick H. CD8+ T cell activation in cancer comprises an initial activation phase in lymph nodes followed by effector differentiation within the tumor. Immunity 2022, 56: 107-124.e5. PMID: 36580918, PMCID: PMC10266440, DOI: 10.1016/j.immuni.2022.12.002.Peer-Reviewed Original ResearchConceptsTumor-draining lymph nodesCD8<sup>+</sup> T cell activationT cell activationCD8<sup>+</sup> T cellsStem-like cellsT cellsCell activationEffector differentiationLymph nodesTumor-specific CD8<sup>+</sup> T cellsActivated CD8<sup>+</sup> T cellsAnti-tumor T cell responsesTumor-draining lymph node cellsCD8+ T cell activationCo-stimulationT cell responsesAntigen-presenting cellsMurine tumor modelsResponse to cancerEffector phenotypeTumor immunotherapyTumor modelTumorCell responsesAcute viruses